Role of HMGB1 in apoptosis-mediated sepsis lethality

被引:321
作者
Qin, Shixin
Wang, Haichao
Yuan, Renqi
Li, Hui
Ochani, Mahendar
Ochani, Kanta
Rosas-Ballina, Mauricio
Czura, Chris J.
Huston, Jared M.
Miller, Ed
Lin, Xinchun
Sherry, Barbara
Kumar, Anjali
LaRosa, Greg
Newman, Walter
Tracey, Kevin J.
Yang, Huan [1 ]
机构
[1] Feinstein Inst Med Res, Lab Biomed Sci, Manhasset, NY 11030 USA
[2] Feinstein Inst Med Res, Ctr Immunol & Inflammat, Manhasset, NY 11030 USA
[3] N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA
[4] N Shore Univ Hosp, Dept Surg, Manhasset, NY 11030 USA
[5] Crit Therapeut Inc, Lexington, MA 02421 USA
关键词
D O I
10.1084/jem.20052203
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Severe sepsis, a lethal syndrome after infection or injury, is the third leading cause of mortality in the United States. The pathogenesis of severe sepsis is characterized by organ damage and accumulation of apoptotic lymphocytes in the spleen, thymus, and other organs. To examine the potential causal relationships of apoptosis to organ damage, we administered Z-VAD-FMK, a broad-spectrum caspase inhibitor, to mice with sepsis. We found that Z-VAD-FMK-treated septic mice had decreased levels of high mobility group box 1 (HMGB1), a critical cytokine mediator of organ damage in severe sepsis, and suppressed apoptosis in the spleen and thymus. In vitro, apoptotic cells activate macrophages to release HMGB1. Monoclonal antibodies against HMGB1 conferred protection against organ damage but did not prevent the accumulation of apoptotic cells in the spleen. Thus, our data indicate that HMGB1 production is downstream of apoptosis on the final common pathway to organ damage in severe sepsis.
引用
收藏
页码:1637 / 1642
页数:6
相关论文
共 23 条
[1]   Epidemiology of sepsis: An update [J].
Angus, DC ;
Wax, RS .
CRITICAL CARE MEDICINE, 2001, 29 (07) :S109-S116
[2]   HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma [J].
Brezniceanu, ML ;
Völp, K ;
Bösse, S ;
Solbach, C ;
Lichter, P ;
Joos, S ;
Zörnig, M .
FASEB JOURNAL, 2003, 17 (08) :1295-+
[3]   HMGB1 in the immunology of sepsis (Not septic shock) and arthritis [J].
Czura, CJ ;
Yang, H ;
Amella, CA ;
Tracey, KJ .
ADVANCES IN IMMUNOLOGY, VOL 84, 2004, 84 :181-200
[4]   Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte [J].
Hotchkiss, RS ;
Chang, KC ;
Swanson, PE ;
Tinsley, KW ;
Hui, JJ ;
Klender, P ;
Xanthoudakis, S ;
Roy, S ;
Black, C ;
Grimm, E ;
Aspiotis, R ;
Han, Y ;
Nicholson, DW ;
Karl, IE .
NATURE IMMUNOLOGY, 2000, 1 (06) :496-501
[5]   Medical progress: The pathophysiology and treatment of sepsis. [J].
Hotchkiss, RS ;
Karl, IE .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) :138-150
[6]   High mobility group box chromosomal protein 1 - A novel proinflammatory mediator in synovitis [J].
Kokkola, R ;
Sundberg, E ;
Ulfgren, AK ;
Palmblad, K ;
Li, J ;
Wang, H ;
Ulloa, L ;
Yang, H ;
Yan, XJ ;
Furie, R ;
Chiorazzi, N ;
Tracey, KJ ;
Andersson, U ;
Harris, HE .
ARTHRITIS AND RHEUMATISM, 2002, 46 (10) :2598-2603
[7]   Recombinant HMGB1 with cytokine-stimulating activity [J].
Li, JH ;
Wang, HC ;
Mason, JM ;
Levine, J ;
Yu, M ;
Ulloa, L ;
Czura, CJ ;
Tracey, KJ ;
Yang, H .
JOURNAL OF IMMUNOLOGICAL METHODS, 2004, 289 (1-2) :211-223
[8]   High-mobility group box 1 protein (HMGB): Nuclear weapon in the immune arsenal [J].
Lotze, MT ;
Tracey, KJ .
NATURE REVIEWS IMMUNOLOGY, 2005, 5 (04) :331-342
[9]   Novel strategies for the treatment of sepsis [J].
Riedemann, NC ;
Guo, RF ;
Ward, PA .
NATURE MEDICINE, 2003, 9 (05) :517-524
[10]   The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness - Functional inactivation of rage in L6 myoblasts results in tumor formation in vivo [J].
Riuzzi, F ;
Sorci, G ;
Donato, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (12) :8242-8253